[go: up one dir, main page]

MX2011011050A - Uso de nifuratel para tratar infecciones causadas por especies de atopobium. - Google Patents

Uso de nifuratel para tratar infecciones causadas por especies de atopobium.

Info

Publication number
MX2011011050A
MX2011011050A MX2011011050A MX2011011050A MX2011011050A MX 2011011050 A MX2011011050 A MX 2011011050A MX 2011011050 A MX2011011050 A MX 2011011050A MX 2011011050 A MX2011011050 A MX 2011011050A MX 2011011050 A MX2011011050 A MX 2011011050A
Authority
MX
Mexico
Prior art keywords
nifuratel
infections
species
atopobium
infections caused
Prior art date
Application number
MX2011011050A
Other languages
English (en)
Inventor
Federico Mailland
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40935525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011011050(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of MX2011011050A publication Critical patent/MX2011011050A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se dirige al uso de nifuratel, o una sal aceptable d& mismo, para tratar infecciones causadas por especies de Atopobium. La invención se dirige además al uso de nifuratel para tratar bacteriura, infección del tracto urinario, infecciones de los genitales exteriores en ambos sexos, así como vaginosis bacteriana, o infecciones vaginales en mujeres, cuando una o más especies del género Atopobium se encuentran entre los patogenos causantes de dichas infecciones.
MX2011011050A 2009-04-20 2010-04-19 Uso de nifuratel para tratar infecciones causadas por especies de atopobium. MX2011011050A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09158221A EP2243482A1 (en) 2009-04-20 2009-04-20 Use of nifuratel to treat infections caused by atopobium species
PCT/EP2010/055090 WO2010121980A1 (en) 2009-04-20 2010-04-19 Use of nifuratel to treat infections caused by atopobium species

Publications (1)

Publication Number Publication Date
MX2011011050A true MX2011011050A (es) 2011-11-02

Family

ID=40935525

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011050A MX2011011050A (es) 2009-04-20 2010-04-19 Uso de nifuratel para tratar infecciones causadas por especies de atopobium.

Country Status (25)

Country Link
US (1) US8673886B2 (es)
EP (2) EP2243482A1 (es)
JP (1) JP2012524117A (es)
KR (1) KR101664889B1 (es)
CN (1) CN102395367B (es)
BR (1) BRPI1015089A2 (es)
CA (1) CA2755328C (es)
CL (1) CL2011002563A1 (es)
CY (1) CY1116209T1 (es)
DK (1) DK2421531T3 (es)
EA (1) EA021557B1 (es)
ES (1) ES2532863T3 (es)
GE (1) GEP20135892B (es)
HR (1) HRP20150306T1 (es)
HU (1) HUE026188T2 (es)
ME (1) ME02141B (es)
MX (1) MX2011011050A (es)
PL (1) PL2421531T3 (es)
PT (1) PT2421531E (es)
RS (1) RS53907B1 (es)
SI (1) SI2421531T1 (es)
SM (1) SMT201500086B (es)
UA (1) UA107346C2 (es)
WO (1) WO2010121980A1 (es)
ZA (1) ZA201106701B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2491929A1 (en) 2011-02-22 2012-08-29 Polichem SA Use of Nifuratel to treat infections caused by Clostridium species
CN102512750A (zh) * 2011-12-27 2012-06-27 上海市计划生育科学研究所 包含克霉唑和硝夫太尔的阴道给药装置及其制备方法
EP2610253A1 (en) 2011-12-27 2013-07-03 Polichem SA Nifuratel sulfoxide for use in the treatment of bacterial infections.
EP2662371A1 (en) * 2012-05-11 2013-11-13 Polichem SA (R)-Nifuratel and synthesis of (R) and (S)-Nifuratel
US9861619B2 (en) 2012-11-01 2018-01-09 The University Of Chicago Antibiotic methods and compositions for bacteria infections
CN111557897B (zh) * 2020-07-07 2023-06-23 温州海鹤药业有限公司 一种含有硝呋太尔的药物组合物及其制备方法
CN112353772A (zh) * 2020-10-20 2021-02-12 北京诚济制药股份有限公司 一种硝呋太尔阴道片及其制备方法
CN112972418B (zh) * 2021-05-18 2021-08-27 北京金城泰尔制药有限公司 硝呋太尔制霉素阴道软胶囊及其制备方法
KR20260006643A (ko) 2023-06-20 2026-01-13 토요 슈가 리파이닝 컴퍼니 리미티드 세균의 증식 억제제, 그것을 포함하는 화장품, 의약 부외품 및 의약 조성물, 그리고 세균의 증식 억제 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008775C (en) 1989-02-24 1998-12-22 Alberto Ferro Nail lacquer
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
EP1506781B1 (de) * 2003-11-03 2005-02-23 Peter-Hansen Volkmann Vaginalpflegezusammensetzung
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
CN100479817C (zh) * 2006-11-24 2009-04-22 门俐俐 硝呋太尔用于制备治疗口腔厌氧菌感染的药物的用途
CN101199474A (zh) * 2007-11-23 2008-06-18 程雪翔 硝呋太尔凝胶及其制备方法

Also Published As

Publication number Publication date
ZA201106701B (en) 2013-03-27
CL2011002563A1 (es) 2012-05-25
KR101664889B1 (ko) 2016-10-12
US20120035124A1 (en) 2012-02-09
KR20110139298A (ko) 2011-12-28
US8673886B2 (en) 2014-03-18
WO2010121980A1 (en) 2010-10-28
ME02141B (me) 2015-10-20
CN102395367A (zh) 2012-03-28
HRP20150306T1 (hr) 2015-04-10
CA2755328C (en) 2016-08-30
HUE026188T2 (hu) 2016-05-30
CN102395367B (zh) 2014-01-29
JP2012524117A (ja) 2012-10-11
PL2421531T3 (pl) 2015-07-31
EA021557B1 (ru) 2015-07-30
SI2421531T1 (sl) 2015-05-29
CA2755328A1 (en) 2010-10-28
CY1116209T1 (el) 2017-02-08
GEP20135892B (en) 2013-07-25
ES2532863T3 (es) 2015-04-01
EP2421531B1 (en) 2015-02-25
EA201171270A1 (ru) 2012-05-30
PT2421531E (pt) 2015-06-29
RS53907B1 (sr) 2015-08-31
EP2243482A1 (en) 2010-10-27
EP2421531A1 (en) 2012-02-29
UA107346C2 (en) 2014-12-25
HK1161837A1 (en) 2012-08-10
BRPI1015089A2 (pt) 2016-04-26
DK2421531T3 (en) 2015-03-23
SMT201500086B (it) 2015-05-05

Similar Documents

Publication Publication Date Title
MX2011011050A (es) Uso de nifuratel para tratar infecciones causadas por especies de atopobium.
WO2010063996A3 (en) Antibacterial compounds
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
MY198204A (en) Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
PL2244722T3 (pl) Leczenie zakażeń drobnoustrojami
PL2227213T3 (pl) Kompozycje i sposoby leczenia zakażeń pochwy oraz chorobotwórczych biofilmów pochwy
MX2011008043A (es) Derivados de actagardina.
PH12013501452A1 (en) Omv vaccine against burkholderia infections
WO2011133929A3 (en) Reducing transmission of sexually transmitted infections
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
PH12019502332A1 (en) Treatment of a bacterial vaginal infection
EP2417258A4 (en) BACTERIOPHAGE COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS
ZA201204249B (en) Treatment of microbial infections
MX342549B (es) Nifuratel sulfoxido para uso en el tratamiento de infecciones bacterianas.
TH133725A (th) การใช้ไนฟูราเทลในการรักษาการติดเชื้อที่เกิดจากเชื้อสปีชีส์ Atopobium
WO2011160048A3 (en) Methods of identifying therapeutic agents for treating persister and bacterial infection
PH12013501523A1 (en) Use of nifuratel to treat infections caused by clostridium species
MD3228G2 (ro) Remediu antibacterian
TH156251A (th) ไนฟูราเทลซัลฟอกไซด์สำหรับการใช้ในการรักษาการติดเชื้อแบคทีเรีย
GB0801768D0 (en) Treatment of microbial infections
UA38583U (ru) 3-МЕТИЛ-7-n-ХЛОРБЕНЗИЛИДЕНГИДРАЗИНОКСАНТИН, КОТОРЫЙ ПРОЯВЛЯЕТ АНТИОКСИДАНТНОЕ ДЕЙСТВИЕ

Legal Events

Date Code Title Description
FG Grant or registration